ADHD drug earns subsidy despite suicidal side effects

A CONTROVERSIAL treatment for attention deficit hyperactivity disorder has been added to the Pharmaceutical Benefits Scheme, despite potential to cause suicidal thoughts and stunt growth. The move comes after a Therapeutic Goods Administration assessment of Strattera last year, which identified suicidal thoughts, agitation, weight loss, chest pain and swollen testicles as potential side effects of the drug.


This entry was posted in Neuroethics.

Comments are closed.